IL6 and congenital rubella syndrome: Patients who died due to COVID-19 were alsofound to have increased markers for CRS, including raised IL-6.[40]It is therefore postulated that the current severe organ dysfunctionobserved in COVID-19 may be due to CRS, and that IL-6 inhibitorssuch as tocilizumab may attenuate this immune reaction.[11,55,56]